1. Home
  2. FNWD vs MDXH Comparison

FNWD vs MDXH Comparison

Compare FNWD & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Finward Bancorp

FNWD

Finward Bancorp

HOLD

Current Price

$37.47

Market Cap

154.0M

Sector

Finance

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$3.42

Market Cap

183.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNWD
MDXH
Founded
1994
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Savings Institutions
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
154.0M
183.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FNWD
MDXH
Price
$37.47
$3.42
Analyst Decision
Buy
Strong Buy
Analyst Count
1
3
Target Price
$34.00
$7.67
AVG Volume (30 Days)
18.5K
134.6K
Earning Date
01-27-2026
02-26-2026
Dividend Yield
1.30%
N/A
EPS Growth
N/A
N/A
EPS
1.88
N/A
Revenue
$66,245,999.00
$103,069,000.00
Revenue This Year
$16.40
$23.34
Revenue Next Year
$5.36
$22.98
P/E Ratio
$19.66
N/A
Revenue Growth
N/A
21.68
52 Week Low
$26.16
$1.35
52 Week High
$39.99
$5.33

Technical Indicators

Market Signals
Indicator
FNWD
MDXH
Relative Strength Index (RSI) 52.69 44.64
Support Level $36.97 $3.45
Resistance Level $38.99 $3.80
Average True Range (ATR) 0.84 0.20
MACD 0.01 -0.02
Stochastic Oscillator 64.78 5.00

Price Performance

Historical Comparison
FNWD
MDXH

About FNWD Finward Bancorp

Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: